Oncology - Coagulation/Bleeding Dz News & Articles

801 Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE) Haemophilia, March 28, 2011

802 Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review British Journal of Haematology, March 25, 2011

803 Identification of factor VIII gene mutations in patients with severe haemophilia A in Venezuela: identification of seven novel mutations Haemophilia, March 25, 2011

804 Clinical assessment of Optivate, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A Haemophilia, March 25, 2011

805 Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia Haemophilia, March 25, 2011    Clinical Article

806 Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A Haemophilia, March 25, 2011

807 Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A Haemophilia, March 25, 2011

808 Application of UKHCDO 2004 guidelines in type 1 von Willebrand Disease - a single centre paediatric experience of the implications of altered or removed diagnosis Haemophilia, March 25, 2011

809 Oral health in adult patients with congenital coagulation disorders - a case control study Haemophilia, March 25, 2011

810 Body structure versus body function in haemophilia: the case of haemophilic ankle arthropathy Haemophilia, March 25, 2011

811 Assessment of musculoskeletal function and mood in haemophilia A adolescents: a cross-sectional study Haemophilia, March 25, 2011

812 Sexual evaluation and treatment of ageing males with haemophilia Haemophilia, March 25, 2011

813 Sources of Thrombomodulin in Pre-Eclampsia: Renal Dysfunction or Endothelial Damage Seminars in Thrombosis and Hemostasis, March 24, 2011

814 Hemostasis in Pre-Eclampsia Seminars in Thrombosis and Hemostasis, March 24, 2011

815 Coagulation and Fibrinolysis in Amniotic Fluid: Physiology and Observations on Amniotic Fluid Embolism, Preterm Fetal Membrane Rupture, and Pre-Eclampsia Seminars in Thrombosis and Hemostasis, March 24, 2011

816 Platelet Function in Pre-Eclampsia Seminars in Thrombosis and Hemostasis, March 24, 2011

817 High Rates of Venous Thromboembolism Prophylaxis Did Not Increase the Incidence of Heparin-Induced Thrombocytopenia Joint Commission Journal on Quality and Patient Safety, March 24, 2011

818 Decidual Hemostasis, Inflammation, and Angiogenesis in Pre-Eclampsia Seminars in Thrombosis and Hemostasis, March 24, 2011

819 Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center Hematology, March 24, 2011

820 Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis Haemophilia, March 24, 2011

1 Management and outcomes for patients with TTP: Analysis of 100 cases at a single institution American Journal of Hematology, April 29, 2013

2 Anticoagulation for prevention and treatment of cancer-related venous thromboembolism British Journal of Haematology, April 9, 2013

3 Adherence to anticoagulant treatment with dabigatran in a real-world setting Journal of Thrombosis and Haemostasis, April 19, 2013
Exclusive Author Commentary

4 Impact of a venous thromboembolism (VTE) prophylaxis smart order set: Improved compliance, fewer events American Journal of Hematology, April 8, 2013

5 Bleeding risk in warfarinized patients with a therapeutic INR: the effect of low factor IX levels Journal of Thrombosis and Haemostasis, April 18, 2013

6 Intracranial haemorrhage in von Willebrand disease: a report on six cases Haemophilia, April 23, 2013

7 Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside British Journal of Haematology, April 25, 2013    Review Article

8 ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment Transfusion, April 10, 2013

9 Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation Thrombosis and Haemostasis, April 23, 2013

10 The predictive ability of bleeding risk stratification models in very old patients on VKA treatment for venous thromboembolism Results of the Prospective Collaborative EPICA study Journal of Thrombosis and Haemostasis, April 15, 2013

11 FcRIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia Journal of Thrombosis and Haemostasis, April 3, 2013

12 Unresponsive thrombotic thrombocytopenic purpura in critically ill adults Intensive Care Medicine, April 5, 2013

13 Statin Therapy and Levels of Hemostatic Factors in a Healthy Population: the Multi-Ethnic Study of Atherosclerosis Journal of Thrombosis and Haemostasis, April 11, 2013

14 Post-thrombotic syndrome: a clinical review Journal of Thrombosis and Haemostasis, March 8, 2013    Review Article

15 Product-dependent anti-factor VIII antibodies Haemophilia, April 25, 2013

16 Anticoagulant use in patients with cancer associated venous thromboembolism: A retrospective cohort study Thrombosis Research, March 22, 2013    Evidence Based Medicine

17 Plasma concentration of protein Z and protein Z-dependent protease inhibitor in patients with haemophilia A Thrombosis Research, April 2, 2013    Evidence Based Medicine

18 Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban Thrombosis Research, April 2, 2013

19 Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study British Journal of Haematology, April 26, 2013    Review Article

20 Successful percutaneous coronary intervention in a patient with combined deficiency of FV and FVIII due to novel compound heterozygous mutations in LMAN1 Haemophilia, April 11, 2013